1. Introduction
The advantages of delivering macromolecular therapeutic agents (i.e., biopharmaceuticals such as proteins and polynucleic acids) via the oral route over the currently used injection routes are well accepted [
1]. Despite this preference and nearly a century of research, no methodology has been identified for the efficient, safe, and consistent delivery of biopharmaceuticals via the oral route. The recent approval of an oral semaglutide tablet by the FDA, however, has provided optimism for at least the oral delivery of therapeutic peptides, although the bioavailability appears to be less than 1% and quite variable [
2,
3]. Unfortunately, methods to enhance the uptake of peptide therapeutics across intestinal epithelia do not appear viable for large biopharmaceuticals due to differences in physicochemical properties and/or the requirement of retaining a more complex native 3D structure. Although the hostile environs of the stomach can be avoided using enteric coated dosage forms, the low permeability of biopharmaceuticals across the intestinal epithelium remains as a limiting barrier [
4,
5]. In the case of peptides, two routes across the epithelium can potentially be used: the paracellular route between adjacent epithelial cells such as the mechanism stimulated by PIP peptides [
6] and transcellular transport in a manner similar to small molecule uptake, which is facilitated by the permeation enhancer, salcaprozate sodium, present in the semaglutide tablet [
7].
A sufficient opening of the paracellular route to support the passage of large biopharmaceuticals, however, carries the risk of introducing unintended substances into the body, potentially causing untoward inflammatory outcomes [
8] and the large molecular size, hydrophilicity and requirement for retention of a native 3D structure of proteins limit the potential for strategies to enhance transcellular uptake. Thus, transcytosis following apical endocytosis and subsequent vesicular trafficking provides the most feasible route across the epithelium for therapeutic proteins [
9]. This transcytosis approach has been explored experimentally for non-selective vesicular uptake, which predominantly occurs at the luminal surface of microfold (M) cells [
10]. As the number of M cells in the human intestine is extremely limited and restricted to selected sites, this approach has not been clinically advanced for oral delivery of biopharmaceuticals.
While there are a number of cell types that make up the intestinal epithelium, enterocytes far outnumber all the others [
11]. A transcytosis pathway across enterocytes has previously been demonstrated for the exotoxin A (PE) virulence factor secreted by
Pseudomonas aeruginosa; a single amino acid deletion in the catalytic domain of PE (deletion of aspartic acid at position 553; ΔE553) renders the protein non-toxic (ntPE) but allows it to retain its transcytosis capacity [
12]. Since incorporating biopharmaceuticals into nanoparticles (NPs) has been shown to prevent their destruction in the intestinal lumen [
13], we postulated that NP transport across the intestinal epithelium could be enhanced by their decoration with ntPE. This possibility was examined in rat jejunum in vivo using biodegradable NPs prepared as an alginate/chitosan condensate (AC NPs-ntPE) with green fluorescent protein (GFP) as a model cargo. Our results provide support for ntPE-directed apical endocytosis and intracellular trafficking to enhance the transcytosis of NPs that could carry a biopharmaceutical payload.
2. Materials and Methods
2.1. Preparation of ntPE-TEV-H6
A non-toxic ΔE553 mutant of Pseudomonas aeruginosa exotoxin A (ntPE) was modified at the C-terminus of the open reading frame to include a consensus sequence for the tobacco etch virus (TEV) protease placed between two cysteine residues and followed by a hexa-histidine sequence (CENLYFQSGTCHHHHHH): ntPE-TEV-H6, was kindly provided by Dr. David FitzGerald (NCI/NIH, Bethesda, MD, USA). SHuffle® T7 E. coli (New England BioLabs, Ipswich, MA, USA) transformed with were induced using 0.5 mM isopropyl β-D-1-thiogalactopyranoside (Fisher Scientific, Loughborough, UK). Cells were harvested by centrifugation at 1530× g at 4 °C for 20 min and suspended in 30 mM Tris-HCl (Sigma-Aldrich, Gillinghamm, UK), 20% sucrose (Sigma-Aldrich, Gillinghamm, UK) at pH 8.0, with 200 mM EDTA (Sigma-Aldrich, Gillinghamm, UK) added dropwise on ice until a final concentration of 1 mM was reached. Following 10 min of gentle shaking, cell suspensions were centrifuged at 3225× g for 20 min at 4 °C, with pellets suspended in ice-cold water and incubated on ice with gentle shaking for 10 min. Following this osmotic shock step, cell debris was pelleted by centrifugation at 3225× g for 20 min at 4 °C and the supernatant, containing proteins from the periplasm, was collected. The ntPE-TEV-H6 protein was captured using a 5 mL prepacked HisTrap HP column (GE Healthcare, Abingdon, UK) and eluted using a linear 20–500 mM gradient of imidazole (Acros Organics, NJ, USA) in a 50 mM Tris pH 8.0 buffer containing 300 mM sodium chloride. Fractions containing the ntPE-TEV-H6 protein were pooled and concentrated using a 10 kDa MWCO Amicon® Ultra-4 Centrifuge Filter (Merck Millipore Ltd., Darmstadt, Germany) prior to size-exclusion chromatography using a Superdex® 200 HR10/30 column (GE Healthcare, Chicago, IL, USA) using PBS at a flow rate of 0.5 mL/min. SDS-PAGE was used to identify column fractions containing ntPE-TEV-H6. Protein concentrations were determined using a NanoDrop™ 2000c spectrophotometer (Thermo Scientific, Wilmington, DE, USA) at 280 nm.
2.2. Preparation of ntPE-GFP and ntPE-hGH
Chimeras of ntPE linked at its C-terminus to the N-terminus of either green fluorescent protein (GFP) or human growth hormone were prepared by the genetic fusion of the non-toxic ΔE553 mutant of
Pseudomonas aeruginosa exotoxin A using expression and purification previously described for this family of toxins [
14].
2.3. Preparation of ntPE for Decorating Nanoparticles (NPs)
First, 2 mg of ntPE-TEV-H6 protein was reacted with TEV enzyme (Life Technologies, Carlsbad, CA, USA) and a 1 mL HisTrap HP column was used to elute the cleaved protein (ntPE-CENLYFQ). A 5-fold molar excess of N-(ε-maleimidocaproic acid) hydrazide (EMCH) was reacted with ntPE at RT for 2 h prior to the removal of unreacted EMCH using dialysis (10 kDa MWCO) against PBS overnight at 4 °C. To prepare a control protein for coupling to NPs, a 3-fold molar excess of Traut’s reagent (5,5′-dithiobis(2-nitrobenzoic acid); Sigma-Aldrich, Gillinghamm, UK) was added to BSA in 12 mM PBS (pH 7.4) containing 3 mM EDTA and incubated at RT for 1 h to produce ~1 thiol group per BSA molecule prior to reaction with EMCH in a manner identical to that used for ntPE-CENLYFQ.
2.4. Preparation of Alginate/Chitosan NPs
First, 2 mL of 0.51 mg/mL calcium chloride (Sigma-Aldrich, Gillinghamm, UK) solution was added to 10 mL of 0.06 mg/mL oxidized alginate solution dropwise under micro-tip probe ultra-sonication (Branson Sonifier Model 2501450, Branson, CT, USA). The resultant material was stirred for another 30 min before the addition of 2 mL of a 0.3 mg/mL aqueous chitosan solution (Sigma-Aldrich, UK) and the suspension equilibrated overnight at RT to allow the formation of NPs. The material was reacted with BSA-EMCH or ntPE-EMCH: 2 mL of these NPs were reacted with 0.5 mg of BSA-EMCH or ntPE-EMCH for 15 min at RT prior to the addition of 4 mg of EDC (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide, Sigma-Aldrich, Gillinghamm, UK) and 5 mg of NHS (
N-hydroxysuccinimide, Thermo Fisher Scientific, Runcorn, UK) to the reaction solution (
Figure 1). After the addition of EDC and NHS, the pH was adjusted to 6.5 and the reaction was allowed to proceed at RT. After 2 h, unreacted protein and reagents were removed by overnight dialysis against water at RT (100 kDa, Spectra/Por
® Biotech membranes, SpectrumLabs, New Brunswick, NJ, USA). The extent of protein coupling onto AC NPs was quantified using the Bradford assay ((Bio-Rad Laboratories, Hercules, CA, USA). After measuring the extent of labelling with ntPE or BSA, remaining aldehyde groups were reacted with an excess of the fluorescent dye Alexa Fluor
® 546 (Ex/Em 490 nm/525 nm) to provide a label for visualization by fluorescence microscopy. GFP-loaded AC NPs were prepared by mixing 0.3 mg of GFP (prepared in lab following expression in
E.coli [
15]) with 2 mL of 0.3 mg/mL chitosan solution, and this mixture was added dropwise into the alginate–calcium complex.
2.5. Measurement of Nanoparticle Size and Zeta Potential
Zeta potential measurements were performed in triplicate using a Malvern ZetaSizer Nano, (Malvern Instruments, Worcestershire, UK) at 25 °C. The hydrodynamic diameter of NPs and particle concentration was measured using a Malvern NanoSight NS 500 instrument, (with all samples diluted 10-fold in PBS prior to measurement. Instrument settings were standardized for measuring each type of NP, with three recordings obtained for each sample. Protein density on each NP preparation was calculated as follows:
with
c being the concentration of protein on NPs in 1 mL,
M being protein molecular weight,
cp being the number of nanoparticles in 1 mL, and
N being Avogadro′s number.
2.6. Transmission Electron Microscopy (TEM)
A morphological analysis of NPs was performed using a transmission electron microscope (TEM; JEOL JEM1200EXII, Jeol, Tokyo, Japan). NP suspensions were diluted 10-fold in PBS (pH 7.4) and dropped onto carbon-coated copper grids (FC300Cu, EM Resolutions, Saffron Walden, UK) with the liquid being quickly removed by touching the edge of the grid with filter paper. Negative staining was performed by exposing samples to 2% uranyl acetate for 30 s, which was also removed by filter paper absorption. Samples were stored in a desiccator after air drying until being viewed in the TEM. At least three batches of each NP were prepared. Representative TEM photos presented in the manuscript were taken from batches prepared on the same date to maximize comparing/characterize NPs. Average NP size was determined from the measurement of 100 randomly selected NPs from different locations on the samples.
2.7. Fourier Transform Infrared Spectroscopy of Alginate/Chitosan NPs
FTIR spectra were obtained by using a Perkin Elmer Frontier Optica FTIR spectrometer (Frontier, Perkin Elmer Ltd, Cambridge, UK) equipped with a mercury cadmium telluride detector. Buffer correction was carried out before each measurement. A drop of AC NPs, AC NPs-BSA and AC NPs-ntPE suspension was placed on the crystal and signals were obtained from 4000 to 600 cm−1 wavenumbers at a resolution of 4 cm−1.
2.8. Oxidation of Alginate
Oxidized alginate was prepared by periodate oxidation [
16]. Briefly, a 1% (
w/
v) sodium alginate (W201502, Sigma-Aldrich, viscosity = 5.0–40.0 cps at 1% in water at RT) solution was mixed with 50 mM sodium periodate (Sigma-Aldrich, Gillinghamm, UK) and incubated at RT for 24 h before quenching with an equimolar amount of ethylene glycol (Sigma-Aldrich, Gillinghamm, UK). Sodium chloride (2.5 g) was added, followed by precipitation with 2 volumes of ethyl alcohol (200 mL). The precipitate was collected by centrifugation and dissolved in 100 mL distilled water prior to a second precipitation using 200 mL ethanol. The resulting product was freeze-dried to yield a white solid (0.8 g, 80% yield).
2.9. In Vivo Transcytosis Assay Protocol
An in vivo protocol, referred as the intraluminal (ILI) injection model, to assess the capacity of test articles to transport across intact rat jejunal epithelium was performed as previously published [
14]. Briefly, male Wistar rats (250–300 g, bred in-house) were anesthetized using isoflurane and a 4–5 cm midline abdominal incision was used to expose the jejunal region of the small intestine. Test articles of ntPE-GFP, AC NPs (AC NPs-ntPE, AC NPs-BSA) or GFP-loaded AC NPs (GFP-AC NPs-ntPE, GFP-AC NPs-BSA), were all administered at 86 µg/mL, were suspended in 250 μL PBS and slowly (~20–30 s) injected into the lumen. Mesentery adjacent to the injection site was denoted with using a permanent marker. At study termination, a 3–5 mm region that captured the marked intestine segment was isolated and processed for microscopic assessment [
14].
2.10. Immunofluorescent Microscopy
Isolated intestinal tissues were fixed in 4% paraformaldehyde at 4 °C for 18–24 h, processed using a Leica TP1020 tissue processor, dehydrated in increasing concentrations of ethanol, cleared with HistoClear (National Diagnostics, Ason Clinton, UK) and infused with molten paraffin wax. Sections cut from tissue-embedded paraffin wax blocks (5 mm thickness; Jung Biocut2035 microtome) were mounted on glass microscope slides, rehydrated, and processed for antigen retrieval by boiling slides in 10 mM sodium citrate for 10 min followed by washing with PBS [
14]. Tissue sections were then permeabilized for 30 min at RT using 0.2% Triton X-100 in PBS and incubated at RT for 2 h in blocking buffer (2% BSA; 2% donkey serum, Sigma-Aldrich; and 0.1% Triton-X 100 in PBS) prior to incubation with primary antibody (rabbit polyclonal anti-
Pseudomonas aeruginosa exotoxin A prepared by our lab, diluted 1:1000) in PBS containing 0.1% Triton X-100 and 1% BSA overnight at 4 °C. GFP was detected with a rabbit polyclonal antibody (Abcam; Ab290) and human growth hormone was detected with a goat polyclonal antibody (R&D systems; AF1067). Excess primary antibody was removed by rinsing in PBS prior to incubation at RT for 2 h in a secondary antibody solution (Alexa Fluor
®® 546-conjugated donkey anti-rabbit polyclonal IgG, diluted 1:100, A10040, Life Technologies, Paisley, UK) containing 0.1% Triton X-100 in PBS. Tissue sections were incubated for 1 h with 200 nM DAPI (4′, 6-diamino-2-phenylindole, Dihydrochloride, D1306, Thermo Fisher Scientific, Runcorn, UK) prior to analysis using a Zeiss LSM 510 microscope. DAPI was detected with an excitation wavelength was 405 nm and the emission wavelength was 462 nm. CD11c
+ cells were detected using the same immunohistochemistry staining as AC NPs using a mouse monoclonal anti-CD11c antibody in the primary antibody solution and Alexa Fluor
®® 488 (Ex/Em 490 nm/525 nm, ab150109, Abcam, diluted 1:100 containing 0.1% Triton X-100 in PBS) conjugated donkey anti-mouse polyclonal IgG in the secondary antibody solution.
4. Discussion
One of the greatest challenges to overcoming the barriers of efficient oral protein delivery is improving the vanishingly small transport capacity of biopharmaceuticals across the intestinal epithelium. We have addressed this challenge by using a bacterial toxin known for its transcytosis properties with the goal of increasing the transcytosis capacity of nanoparticles (NPs). In the studies presented, we show that a non-toxic version of exotoxin A derived from
Pseudomonas aeruginosa (ntPE) can be used to transport a protein cargo (GFP) across intact intestinal epithelia. Further, we describe methods to efficiently and selectively couple ntPE onto biodegradable NPs prepared from alginate and chitosan (AC). Our results show that chemical conjugation of ntPE can dramatically enhance the capacity of AC NPs to transport across rat jejunum epithelium
in vivo. BSA, which is of similar molecular size and has a comparable pI to ntPE, coupled similarly to AC NPs failed to elicit this effect. We also attempted to match the frequency of coupling of ntPE and BSA on NPs that were being compared for transcytosis. Thus, the concept of using ntPE to facilitate receptor-mediated vesicular transcytosis of NPs was consistent with the data obtained. It is important to point out, however, that due to uncertainties of NP stability, distribution, and access the intestinal epithelium following intraluminal injection, it is unclear how much of the administered dose reached the epithelium for uptake. Based upon these same unknowns, we also do not know if there would be linearity for lower or higher doses to reach the epithelium. Importantly, none of the tissues we examined showed any signs of overt toxicity and studies by others where alginate-chitosan NPs were administrated orally described toxicity, similar to observations reported by others [
25].
While a variety of NPs have been examined for the oral delivery of biopharmaceuticals, we believe this is the first description of using a ntPE-mediated transcytosis pathway to improve the uptake efficiency of a biodegradable NP capable of carrying a macromolecular cargo across the intestinal epithelium. Our data suggests that the NPs used in these studies were sufficiently stable to compete the transcytosis process following administration into the lumen of the rat jejunum. NPs coupled to ntPE failed to show extensive retention in epithelial cells after endocytosis and did not seem to be sequestered into large lysosome-like structures within these cells [
14]. This pattern suggests that the transcytosis pathway accessed by ntPE exhibited limited entry into the lysosomal degradation pathway, implying that the hijacking of a vesicular trafficking resulting in basolateral membrane targeting and not a lysosomal fate within epithelial cells. At present, it is unclear what vesicular compartments are accessed by ntPE that could direct NPs away from the typical default pathway of lysosomal destruction. In this regard, NPs made from a polyanhydride copolymer of fumaric and sebacic acids are taken up by absorptive enterocytes and have been observed within the Golgi apparatus and secretory vesicles near the lateral edge of the cells, suggesting that after enterocyte entry some types of NPs do not traffic by default to lysosomes [
26]. Thus, it is possible that ntPE may provide a similar routing via the Golgi apparatus.
The scavenger receptor low-density lipoprotein-receptor-like protein 1 (LRP-1) has been shown to be involved in the endocytosis of PE, and ntPE, preceding its transcytosis across polarized epithelial cells [
12]. LRP-1 is also expressed on professional antigen presenting cells located just beneath epithelial surfaces of the body, and ntPE has been previously investigated for the delivery of peptide antigens to these cells for the purposes of intranasal vaccination [
21]. Some studies have shown that NPs taken up by mouse intestine can end up in CD11c
+ cells [
27]. Importantly, these previous studies showed that 20–40 nm NPs can be taken up by enterocytes, but that NPs larger than 100 nm require uptake across epithelial cells overlying Peyer’s patches [
27]. Our studies have shown that NPs which are roughly twice this size (~200 nm) at the time of application into the jejunum can also undergo transcytosis across absorptive enterocytes using a mechanism accessed by ntPE and can also result in materials being taken up into CD11c
+ cells. These 200 nm particles could represent aggregates of NPs and that during transcytosis, the size of these particles may be dynamic as they traffic through the cellular vesicular system to complete the transcytosis process.
In general, NP transcytosis in the intestine is poor due to the natural defence mechanisms of the epithelium, which maintains the body’s homeostatic state in the face of massive numbers of dietary NP-size materials and viral exposure. Several transcytosis pathways associated with receptor-mediated endocytosis mechanisms have been explored to overcome this issue: Vitamin B
12, lectins, IgG, and bacterial toxins [
6]. We have examined a specific virulence factor secreted from
Pseudomonas aeruginosa known as exotoxin A (PE) to improve the apical to basal transport of NPs across intestinal epithelial cells. PE’s role in the pathophysiology of mucosal
Pseudomonas aeruginosa infection has been suggested to involve local targeting of antigen presentation cells (APCs) such as macrophages and dendritic cells that would result in the ultimate apoptosis of these cells [
22]. Importantly, the genetic deletion of a glutamic acid at position 553 of PE results in a completely non-toxic version of PE (ntPE) [
28]. Relevant to the studies described herein, PE has been shown to efficiently transport across intact polarized epithelia to target APCs in the underlying
lamina propria and ntPE has been shown to retain these transcytosis and APC targeting characteristics.
Overall, we have provided evidence that the transcytosis pathway accessed by PE could be used to enhance the apical to basolateral delivery of NPs and showed that ntPE appears capable of facilitating endocytosis and transcytosis of NPs in the order of 100 nm diameter. The apparent preference for CD11c+ cells in the lamina propria following this transcytosis process suggests that ntPE-decorated NPs may have a use in oral immune system regulation: vaccination, tolerization, etc. Additionally, the AC NPs used in these studies were shown to carry a macromolecule (GFP) that could be replaced with a cargo appropriate for an oral immunization outcome.